The Scientific World Journal

Review Article

Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis

Table 2

Rates of thrombotic events in the two groups with different duration of dual antiplatelet therapy.
Study ID Total number in short duration group Total number in longer duration group Stent thrombosis Myocardial infarction Stroke Revascularization Cerebrovascular
death		 All-cause mortality Death and myocardial infarction
ShortLongShortLongShortLongShortLongShortLongShortLongShort Long
Gwon et al. 2012 (EXCELLENT trial) [6]7227216 (0.9%)
definite
0 (0%) probable		0 definite
1 (0.1%) probable		13
(1.8%) 		7
(1%)		3 (0.4%)5 (0.7%)Target lesion revascularization 17 (2.4%)
Target vessel revascularization 22 (3.1%)
Any 43 (6.2%)		Target lesion revascularization 18 (2.8%)
Target vessel revascularization 22 (3.2%)
Any 43 (6.2%)		2 
(0.3%)		3 
(0.4%)		4 
(0.6%)		7 
(1%)		17 
(2.4%)		14 
(1.9%)
Hu and Wang 2012 [10]8894Incidence 0.2% definite or probableIncidence 0%
definite or probable		Incidence
0.2%		Incidence
1%		NANANANANANAIncidence 2.6%Incidence 2.3%NANA
Kim et al. 2012 (RESET trial) [7]1,0591,0582 (0.2%)
definite or probable		3 (0.3%)
definite or probable		2
(0.2%)		4
(0.4%)		6 (0.6%)6 (0.7%)Target vessel revascularization 31 (3.9%)Target vessel revascularization 27 (3.7%)2 
(0.2%)		4 
(0.4%)		5 
(0.5%)		8 
(1%)		7 
(0.7%)		11 
(1.0%)
Park et al. 2010 (REAL-LATE and ZEST-LATE) [8]1,3441,3574 definite (0.3%)5 definite (0.4%)7
(0.5%)		10
(0.7%)		4 (0.3%)9 (0.7%)Any 26 (2.4%)Any 36 (3.1%)NANA13 
(10%)		20 
(15%)		17 
(1.3%)		27 
(2.0%)
Valgimigli et al. 2012 (PRODIGY) [9]9839877 definite (0.7%), 15 definite or probable (1.5%),
46 definite or probable or possible (4.7%)		8 definite (0.8%), 13 definite or probable (1.3%), 38 definite or probable or possible (3.9%)41
(4.2%) 		39
(4%) 		14 (1.4%) 21 (2.1%)NANA37 
(3.8%)		36 
(3.7%) 		65 
(6.6%)		65 
(6.6%)		94 
(9.6%)		88 
(8.9%)